医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Synergy Biomedical Announces Regulatory Clearance and Launch of BIOSPHERE PUTTY in Australia

2018年03月06日 PM11:00
このエントリーをはてなブックマークに追加


 

COLLEGEVILLE, Pa.

Synergy Biomedical, LLC, a developer of orthobiologic and biomaterial products, announced that it has received Therapeutic Goods Administration (TGA) clearance in Australia for its bioactive bone graft, BIOSPHERE PUTTY. BIOSPHERE PUTTY is an advanced synthetic bone graft product that has previously received FDA and CE Mark clearances, and has been on the market since 2013.

“We are very pleased with our TGA clearance and are excited to launch this innovative, synthetic bone graft in Australia,” indicated Dr. Mark Borden, Ph.D., President/CEO of Synergy. “This clearance enables more surgeons worldwide access to our next-generation bone graft technology.”

“The launch of BioSphere Putty in Australia represents a significant milestone in expanding our distribution across the globe,” stated Kevin Booth, VP of Sales. “The Australian market provides Synergy with a sizable opportunity to grow our BioSphere Putty sales.”

BIOSPHERE PUTTY is a synthetic bone graft that utilizes a unique, spherical form of bioactive glass in combination with a resorbable carrier. The product provides surgeons with a moldable bone graft material that is easy to use and compatible with a variety of bone grafting techniques. Based on the Company’s patented BioSphere Technology, BIOSPHERE PUTTY has been shown in vivo to significantly improve the healing potential of bioactive glass. The use of spherical particles allows for precise control over the properties of bioactive glass, and results in an optimal bone healing response. BIOSPHERE PUTTY is the first of several bioactive glass products being developed by Synergy Biomedical.

About Synergy Biomedical, LLC

Founded in 2011, Synergy Biomedical is a privately-held medical device company focused on bringing innovative biomaterial-based products to the musculoskeletal market. The Company’s BioSphere Technology has broad, cross-platform surgical applications in the orthopaedic, spine, sports medicine, and joint arthroplasty markets. This technology represents a unique approach to advancing bone healing, and improving patient outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180306005917/en/

CONTACT

Synergy Biomedical, LLC
Mark Borden, Ph.D.
President/CEO
484-902-8141
www.synergybiomedical.com
info@synergybiomedical.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Takeda to Divest TachoSil® to Corza Health for €350 Million
  • 新たな研究:ハンドドライヤーによる手の乾燥はペーパータオルと同じくらい衛生的
  • Body Fit Training PTY LTD Sues to Invalidate F45 Training PTY LTD’s U.S. Patents
  • Singapore and Apple Partner on National Health Initiative Using Apple Watch
  • 最新研究:干手机与用纸巾擦干双手一样卫生